Sean Stalfort
Director/Board Member at TAYSHA GENE THERAPIES, INC.
Net worth: 11 M $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Paul Manning | M | 68 |
PBM Pharmaceuticals, Inc.
 PBM Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology PBM Pharmaceuticals, Inc. manufactures pharmaceutical products. The private company is based in Charlottesville, VA.
PBM Capital Group LLC
 PBM Capital Group LLC Investment ManagersFinance PBM Capital Group LLC (PBM Capital Group) is a private equity and venture capital firm founded in 2010 by Paul B. Manning. The firm is headquartered in Charlottesville, Virginia.
Tolerion, Inc.
 Tolerion, Inc. Pharmaceuticals: MajorHealth Technology Tolerion, Inc. operates as a clinical-stage biopharmaceutical firm. It develops and commercializes therapeutics. The firm provides TOL-3034 and TOL-3052 to treat myasthenia gravis and neuromyelitis optica. The company was founded by Lawrence J. Steinman and is headquartered in South San Francisco, CA.
Xalud Therapeutics, Inc.
 Xalud Therapeutics, Inc. BiotechnologyHealth Technology Xalud Therapeutics, Inc. develops novel therapies with several promising therapeutic programs for inflammatory. The firm offers XT-101, a single dosage injection that stops disease progression, eliminates neuropathic pain, and reverses paralysis. It also researches on the applicability of XT-101 for multiple sclerosis and amyotrophic lateral sclerosis. The company was founded by John Forsayeth and Linda Watkins and is headquartered in San Francisco, CA. | 14 years |
| Sukumar Nagendran | M | 58 |
SalioGen Therapeutics, Inc.
 SalioGen Therapeutics, Inc. BiotechnologyHealth Technology SalioGen Therapeutics, Inc. is a genetic medicine company based in Cambridge, MA. The company is advancing the Exact DNA Integration Technology (EDIT) platform, which is a mammal-derived genome engineering technology for use in potentially curative non-viral gene therapy. SalioGen Therapeutics has launched Gene Coding, a genetic medicine technology, to develop durable, broadly applicable genetic medicines using its EDIT platform. The company's mission is to transform the treatment paradigm for patients with inherited disorders. Jason F. Cole has been the CEO of the company since 2023. | 4 years |
| Christopher Hayes | M | 60 | 6 years | |
| Ted White | M | 59 | 7 years | |
| Sean Nolan | M | 56 | 4 years | |
| Joseph Higgins | M | - |
SalioGen Therapeutics, Inc.
SalioGen Therapeutics, Inc. BiotechnologyHealth Technology SalioGen Therapeutics, Inc. is a genetic medicine company based in Cambridge, MA. The company is advancing the Exact DNA Integration Technology (EDIT) platform, which is a mammal-derived genome engineering technology for use in potentially curative non-viral gene therapy. SalioGen Therapeutics has launched Gene Coding, a genetic medicine technology, to develop durable, broadly applicable genetic medicines using its EDIT platform. The company's mission is to transform the treatment paradigm for patients with inherited disorders. Jason F. Cole has been the CEO of the company since 2023. | 4 years |
| Daniel O'Connell | M | 54 | 18 years | |
| Gary Goldenberg | M | 47 | 6 years | |
| Stephen D. Collins | M | - |
Xalud Therapeutics, Inc.
Xalud Therapeutics, Inc. BiotechnologyHealth Technology Xalud Therapeutics, Inc. develops novel therapies with several promising therapeutic programs for inflammatory. The firm offers XT-101, a single dosage injection that stops disease progression, eliminates neuropathic pain, and reverses paralysis. It also researches on the applicability of XT-101 for multiple sclerosis and amyotrophic lateral sclerosis. The company was founded by John Forsayeth and Linda Watkins and is headquartered in San Francisco, CA. | - |
| John R. Donovan | M | - |
Tolerion, Inc.
Tolerion, Inc. Pharmaceuticals: MajorHealth Technology Tolerion, Inc. operates as a clinical-stage biopharmaceutical firm. It develops and commercializes therapeutics. The firm provides TOL-3034 and TOL-3052 to treat myasthenia gravis and neuromyelitis optica. The company was founded by Lawrence J. Steinman and is headquartered in South San Francisco, CA. | 5 years |
| Philip Donenberg | M | 63 | 4 years | |
| Derrell Porter | M | 53 | 1 years | |
| Lawrence Eichenfield | M | 66 | 4 years | |
| Stephen Zachary | M | 42 |
Tolerion, Inc.
Tolerion, Inc. Pharmaceuticals: MajorHealth Technology Tolerion, Inc. operates as a clinical-stage biopharmaceutical firm. It develops and commercializes therapeutics. The firm provides TOL-3034 and TOL-3052 to treat myasthenia gravis and neuromyelitis optica. The company was founded by Lawrence J. Steinman and is headquartered in South San Francisco, CA. | - |
| John P. Donoghue | M | 75 |
Brown University
| 33 years |
| Kamran Alam | M | 46 | 4 years | |
| Laura Sepp-Lorenzino | M | 63 | 4 years | |
| Diem Nguyen | M | 52 | 4 years | |
| Laura Stoppel | M | 38 | 4 years | |
| Mike Huston | M | - |
Xalud Therapeutics, Inc.
Xalud Therapeutics, Inc. BiotechnologyHealth Technology Xalud Therapeutics, Inc. develops novel therapies with several promising therapeutic programs for inflammatory. The firm offers XT-101, a single dosage injection that stops disease progression, eliminates neuropathic pain, and reverses paralysis. It also researches on the applicability of XT-101 for multiple sclerosis and amyotrophic lateral sclerosis. The company was founded by John Forsayeth and Linda Watkins and is headquartered in San Francisco, CA. | - |
| Fred Porter | M | - | - | |
| Nathan Fountain | M | 61 | 3 years | |
| Steve Reynolds | M | - | 3 years | |
| Michael Ward | M | - |
Benevolent Capital Partners LLC (Private Equity)
 Benevolent Capital Partners LLC (Private Equity) Investment ManagersFinance Benevolent Capital Partners LLC (Private Equity) (Benevolent Capital) is a private equity and venture capital firm founded in 2005 by Brett M. Johnson and Grant D. Johnson. The firm is headquartered in Charlottesville, Virginia. | 17 years |
| Derek Meisner | M | 53 | 2 years | |
| Matthew Zuga | M | 58 | 3 years | |
| Mark Prygocki | M | 58 | 6 years | |
| Jason Cole | M | 51 |
SalioGen Therapeutics, Inc.
SalioGen Therapeutics, Inc. BiotechnologyHealth Technology SalioGen Therapeutics, Inc. is a genetic medicine company based in Cambridge, MA. The company is advancing the Exact DNA Integration Technology (EDIT) platform, which is a mammal-derived genome engineering technology for use in potentially curative non-viral gene therapy. SalioGen Therapeutics has launched Gene Coding, a genetic medicine technology, to develop durable, broadly applicable genetic medicines using its EDIT platform. The company's mission is to transform the treatment paradigm for patients with inherited disorders. Jason F. Cole has been the CEO of the company since 2023. | 1 years |
| Jeffrey Ives | M | 73 | 10 years | |
| Jayson M. Rieger | M | 48 |
PBM Capital Group LLC
PBM Capital Group LLC Investment ManagersFinance PBM Capital Group LLC (PBM Capital Group) is a private equity and venture capital firm founded in 2010 by Paul B. Manning. The firm is headquartered in Charlottesville, Virginia.
Xalud Therapeutics, Inc.
Xalud Therapeutics, Inc. BiotechnologyHealth Technology Xalud Therapeutics, Inc. develops novel therapies with several promising therapeutic programs for inflammatory. The firm offers XT-101, a single dosage injection that stops disease progression, eliminates neuropathic pain, and reverses paralysis. It also researches on the applicability of XT-101 for multiple sclerosis and amyotrophic lateral sclerosis. The company was founded by John Forsayeth and Linda Watkins and is headquartered in San Francisco, CA. | 10 years |
| Kimberlee Drapkin | F | 55 | 2 years | |
| Craig Ballaron | M | 63 | 5 years | |
| Eric Siemers | M | 68 | 6 years | |
| Pat Sacco | M | - |
SalioGen Therapeutics, Inc.
SalioGen Therapeutics, Inc. BiotechnologyHealth Technology SalioGen Therapeutics, Inc. is a genetic medicine company based in Cambridge, MA. The company is advancing the Exact DNA Integration Technology (EDIT) platform, which is a mammal-derived genome engineering technology for use in potentially curative non-viral gene therapy. SalioGen Therapeutics has launched Gene Coding, a genetic medicine technology, to develop durable, broadly applicable genetic medicines using its EDIT platform. The company's mission is to transform the treatment paradigm for patients with inherited disorders. Jason F. Cole has been the CEO of the company since 2023. | 2 years |
| Alison Long | M | - | 1 years | |
| Craig Gordon | M | - |
SalioGen Therapeutics, Inc.
SalioGen Therapeutics, Inc. BiotechnologyHealth Technology SalioGen Therapeutics, Inc. is a genetic medicine company based in Cambridge, MA. The company is advancing the Exact DNA Integration Technology (EDIT) platform, which is a mammal-derived genome engineering technology for use in potentially curative non-viral gene therapy. SalioGen Therapeutics has launched Gene Coding, a genetic medicine technology, to develop durable, broadly applicable genetic medicines using its EDIT platform. The company's mission is to transform the treatment paradigm for patients with inherited disorders. Jason F. Cole has been the CEO of the company since 2023. | - |
| Charles Cleeland | M | - |
Xalud Therapeutics, Inc.
Xalud Therapeutics, Inc. BiotechnologyHealth Technology Xalud Therapeutics, Inc. develops novel therapies with several promising therapeutic programs for inflammatory. The firm offers XT-101, a single dosage injection that stops disease progression, eliminates neuropathic pain, and reverses paralysis. It also researches on the applicability of XT-101 for multiple sclerosis and amyotrophic lateral sclerosis. The company was founded by John Forsayeth and Linda Watkins and is headquartered in San Francisco, CA. | - |
| Ronald Dubner | M | - |
Xalud Therapeutics, Inc.
Xalud Therapeutics, Inc. BiotechnologyHealth Technology Xalud Therapeutics, Inc. develops novel therapies with several promising therapeutic programs for inflammatory. The firm offers XT-101, a single dosage injection that stops disease progression, eliminates neuropathic pain, and reverses paralysis. It also researches on the applicability of XT-101 for multiple sclerosis and amyotrophic lateral sclerosis. The company was founded by John Forsayeth and Linda Watkins and is headquartered in San Francisco, CA. | - |
| Gerald Gebhart | M | - |
Xalud Therapeutics, Inc.
Xalud Therapeutics, Inc. BiotechnologyHealth Technology Xalud Therapeutics, Inc. develops novel therapies with several promising therapeutic programs for inflammatory. The firm offers XT-101, a single dosage injection that stops disease progression, eliminates neuropathic pain, and reverses paralysis. It also researches on the applicability of XT-101 for multiple sclerosis and amyotrophic lateral sclerosis. The company was founded by John Forsayeth and Linda Watkins and is headquartered in San Francisco, CA. | - |
| Sean McAuliffe | M | - | 4 years | |
| Daniel Lammertse | M | - |
Xalud Therapeutics, Inc.
Xalud Therapeutics, Inc. BiotechnologyHealth Technology Xalud Therapeutics, Inc. develops novel therapies with several promising therapeutic programs for inflammatory. The firm offers XT-101, a single dosage injection that stops disease progression, eliminates neuropathic pain, and reverses paralysis. It also researches on the applicability of XT-101 for multiple sclerosis and amyotrophic lateral sclerosis. The company was founded by John Forsayeth and Linda Watkins and is headquartered in San Francisco, CA. | - |
| Lee F. Allen | M | 72 | 7 years | |
| Julie Bockenstette | F | - | - | |
| Siew Tin Gan | F | - | - | |
| Jasna Jerecic | M | - | - | |
| Amber Dilley | F | - | 3 years | |
| Kasey Spencer | M | - | - | |
| Kathleen Pierce | F | - | - | |
| Hayleigh Collins | M | - | - | |
| Terence Kohler | M | 46 | 3 years | |
| Mahmood Ladha | M | 60 | 5 years | |
| Janice Hitchcock | M | - | 6 years | |
| Mary Newman | F | 65 | 3 years | |
| Jim Doherty | M | 56 | - | |
| Per Richard Torbjörn Hallberg | M | 55 | 5 years | |
| Jim Rouse | M | - | - | |
| Bill L. Nichols | M | - | 6 years | |
| Michelle Girard | F | - |
NatWest Markets Securities, Inc.
 NatWest Markets Securities, Inc. Investment Banks/BrokersFinance Founded in 1985, NatWest Markets Securities, Inc. is a financial services and brokerage firm headquartered in Stamford, Connecticut. The firm is a subsidiary of RBS Holdings USA, Inc. and their ultimate parent is the Royal Bank of Scotland Plc (LSE: RBS). The firm was formerly known as RBS Securities, Inc., RBS Greenwich Capital, and Greenwich Capital Markets, Inc. NatWest is an institutional fixed-income firm that provides a full range of debt capital markets services to both those seeking to raise capital and those seeking to invest it. The firm is an industry leader in the U.S. Treasury, agency and MBS markets and in providing real estate and asset-backed financing to their clients. NatWest also provides futures brokerage services and trade strategies to select clients. | 20 years |
| Joe Pedersen | M | - |
PBM Capital Group LLC
PBM Capital Group LLC Investment ManagersFinance PBM Capital Group LLC (PBM Capital Group) is a private equity and venture capital firm founded in 2010 by Paul B. Manning. The firm is headquartered in Charlottesville, Virginia. | - |
| Joe Bonaccorso | M | 60 | 6 years | |
| Guido Oelkers | M | 59 | 5 years | |
| Russell Barton | M | 66 | 5 years | |
| Joseph Silverman | M | - |
Brown University
| 36 years |
| Sung You | F | - |
PBM Capital Group LLC
PBM Capital Group LLC Investment ManagersFinance PBM Capital Group LLC (PBM Capital Group) is a private equity and venture capital firm founded in 2010 by Paul B. Manning. The firm is headquartered in Charlottesville, Virginia. | - |
| Tracy M. Porter | F | - | 3 years | |
| Henrik Stenqvist | M | 57 | 5 years | |
| Emily McGinnis | F | - | 4 years | |
| Alexandria Braun | F | - | 2 years | |
| Brendan O’Leary | M | - |
Xalud Therapeutics, Inc.
Xalud Therapeutics, Inc. BiotechnologyHealth Technology Xalud Therapeutics, Inc. develops novel therapies with several promising therapeutic programs for inflammatory. The firm offers XT-101, a single dosage injection that stops disease progression, eliminates neuropathic pain, and reverses paralysis. It also researches on the applicability of XT-101 for multiple sclerosis and amyotrophic lateral sclerosis. The company was founded by John Forsayeth and Linda Watkins and is headquartered in San Francisco, CA. | 3 years |
| Robyn Moxon | F | - | 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| A. Davis | M | 57 | 2 years | |
| Douglas L. Blankenship | M | - | 1 years | |
| Alex Sapir | M | 57 | 2 years | |
| David Zaccardelli | M | 59 | 1 years | |
| Jay Levine | M | 61 |
NatWest Markets Securities, Inc.
NatWest Markets Securities, Inc. Investment Banks/BrokersFinance Founded in 1985, NatWest Markets Securities, Inc. is a financial services and brokerage firm headquartered in Stamford, Connecticut. The firm is a subsidiary of RBS Holdings USA, Inc. and their ultimate parent is the Royal Bank of Scotland Plc (LSE: RBS). The firm was formerly known as RBS Securities, Inc., RBS Greenwich Capital, and Greenwich Capital Markets, Inc. NatWest is an institutional fixed-income firm that provides a full range of debt capital markets services to both those seeking to raise capital and those seeking to invest it. The firm is an industry leader in the U.S. Treasury, agency and MBS markets and in providing real estate and asset-backed financing to their clients. NatWest also provides futures brokerage services and trade strategies to select clients. | 8 years |
| Grant A. Krafft | M | - | 24 years | |
| William F. Goure | M | - | 15 years | |
| Wendy Nelson | M | - |
Brown University
| 8 years |
| Sridhar Ramaswamy | M | 58 |
Brown University
| 5 years |
| Chris Degnan | M | 44 | 1 years | |
| Jeffrey Sevigny | M | 55 | 3 years | |
| Adam Russell Stauffer | M | - |
Brown University
| 5 years |
| Shou Kang Lin | M | 60 |
Brown University
| 4 years |
| Robert P. Goldman | M | - |
Brown University
| 4 years |
| Margaret Kerins | F | - |
NatWest Markets Securities, Inc.
NatWest Markets Securities, Inc. Investment Banks/BrokersFinance Founded in 1985, NatWest Markets Securities, Inc. is a financial services and brokerage firm headquartered in Stamford, Connecticut. The firm is a subsidiary of RBS Holdings USA, Inc. and their ultimate parent is the Royal Bank of Scotland Plc (LSE: RBS). The firm was formerly known as RBS Securities, Inc., RBS Greenwich Capital, and Greenwich Capital Markets, Inc. NatWest is an institutional fixed-income firm that provides a full range of debt capital markets services to both those seeking to raise capital and those seeking to invest it. The firm is an industry leader in the U.S. Treasury, agency and MBS markets and in providing real estate and asset-backed financing to their clients. NatWest also provides futures brokerage services and trade strategies to select clients. | 9 years |
| John Sheehan | M | - |
NatWest Markets Securities, Inc.
NatWest Markets Securities, Inc. Investment Banks/BrokersFinance Founded in 1985, NatWest Markets Securities, Inc. is a financial services and brokerage firm headquartered in Stamford, Connecticut. The firm is a subsidiary of RBS Holdings USA, Inc. and their ultimate parent is the Royal Bank of Scotland Plc (LSE: RBS). The firm was formerly known as RBS Securities, Inc., RBS Greenwich Capital, and Greenwich Capital Markets, Inc. NatWest is an institutional fixed-income firm that provides a full range of debt capital markets services to both those seeking to raise capital and those seeking to invest it. The firm is an industry leader in the U.S. Treasury, agency and MBS markets and in providing real estate and asset-backed financing to their clients. NatWest also provides futures brokerage services and trade strategies to select clients.
Brown University
| 8 years |
| Modassir S. Choudhry | M | - |
Brown University
| 7 years |
| Symon Drake-Brockman | M | 62 |
NatWest Markets Securities, Inc.
NatWest Markets Securities, Inc. Investment Banks/BrokersFinance Founded in 1985, NatWest Markets Securities, Inc. is a financial services and brokerage firm headquartered in Stamford, Connecticut. The firm is a subsidiary of RBS Holdings USA, Inc. and their ultimate parent is the Royal Bank of Scotland Plc (LSE: RBS). The firm was formerly known as RBS Securities, Inc., RBS Greenwich Capital, and Greenwich Capital Markets, Inc. NatWest is an institutional fixed-income firm that provides a full range of debt capital markets services to both those seeking to raise capital and those seeking to invest it. The firm is an industry leader in the U.S. Treasury, agency and MBS markets and in providing real estate and asset-backed financing to their clients. NatWest also provides futures brokerage services and trade strategies to select clients. | 8 years |
| Nancy Wysenski | F | 66 | 1 years | |
| Jeffrey Green | M | - |
Brown University
| 7 years |
| Mohan Balachandran | M | - |
Brown University
| 5 years |
| Steven M. Goldman | M | 72 | 2 years | |
| Scott Friend | M | 59 |
Brown University
| 4 years |
| Alfred Novak | M | 76 | 2 years | |
| Jo Ann Corkran | F | - |
NatWest Markets Securities, Inc.
NatWest Markets Securities, Inc. Investment Banks/BrokersFinance Founded in 1985, NatWest Markets Securities, Inc. is a financial services and brokerage firm headquartered in Stamford, Connecticut. The firm is a subsidiary of RBS Holdings USA, Inc. and their ultimate parent is the Royal Bank of Scotland Plc (LSE: RBS). The firm was formerly known as RBS Securities, Inc., RBS Greenwich Capital, and Greenwich Capital Markets, Inc. NatWest is an institutional fixed-income firm that provides a full range of debt capital markets services to both those seeking to raise capital and those seeking to invest it. The firm is an industry leader in the U.S. Treasury, agency and MBS markets and in providing real estate and asset-backed financing to their clients. NatWest also provides futures brokerage services and trade strategies to select clients.
Greenwich Capital Holdings, Inc.
| 2 years |
| Glenn A. Oclassen | M | 81 | 4 years | |
| Roger Jeffs | M | 62 | 2 years | |
| Martha Goss | F | 74 |
Brown University
| 31 years |
| Ted L. Knetzger | M | 72 |
NatWest Markets Securities, Inc.
NatWest Markets Securities, Inc. Investment Banks/BrokersFinance Founded in 1985, NatWest Markets Securities, Inc. is a financial services and brokerage firm headquartered in Stamford, Connecticut. The firm is a subsidiary of RBS Holdings USA, Inc. and their ultimate parent is the Royal Bank of Scotland Plc (LSE: RBS). The firm was formerly known as RBS Securities, Inc., RBS Greenwich Capital, and Greenwich Capital Markets, Inc. NatWest is an institutional fixed-income firm that provides a full range of debt capital markets services to both those seeking to raise capital and those seeking to invest it. The firm is an industry leader in the U.S. Treasury, agency and MBS markets and in providing real estate and asset-backed financing to their clients. NatWest also provides futures brokerage services and trade strategies to select clients. | 22 years |
| Kathleen Reape | M | 58 | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 64 | 64.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Sean Stalfort
- Personal Network
